Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 18/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | ATIC | P31939 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18392411 | 1.00 | MCL1 (1.00) | MCL1CYP2C9HSD17B10BCL2L1THRB | |
| SCHEMBL8112005 | 0.81 | MCL1 (0.68) | MCL1CYP2C9HSD17B10BCL2L1HPGD | |
| SCHEMBL1808593 | 0.81 | MCL1 (0.73) | MCL1CYP2C9HSD17B10BCL2L1THRB | |
| SCHEMBL28981270 | 0.80 | MCL1 (0.66) | MCL1CYP2C9HSD17B10HPGDTSHR | |
| SCHEMBL7234615 | 0.80 | MCL1 (0.71) | MCL1CYP2C9HSD17B10BCL2L1THRB | |
| SCHEMBL590115 | 0.80 | MCL1 (0.71) | MCL1CYP2C9HSD17B10BCL2L1THRB | |
| SCHEMBL589651 | 0.80 | MCL1 (1.00) | MCL1CYP2C9HSD17B10BCL2L1THRB | |
| SCHEMBL29539793 | 0.80 | MCL1 (0.71) | MCL1CYP2C9HSD17B10BCL2L1THRB | |
| SCHEMBL2789013 | 0.78 | MCL1 (0.69) | MCL1CYP2C9HSD17B10BCL2L1THRB | |
| SCHEMBL5515234 | 0.75 | MCL1 (0.59) | MCL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396549-A1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEROF | UNIV MARYLAND (US) | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396549-A1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEROF | MCL1, TP53, MYC | MCL1 1/4885CYP2C9 4854/4885HSD17B10 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.